1. Speedel - Company Profile | LinkedIn
This is the limited version of the Speedel company profile: Join LinkedIn or Sign In to see more information. Speedel Holding, Ltd., a biopharmaceutical company, engages in the ...
2. Speedel Announces Start of SPP635 Phase IIa Trial in Diabetic ...
- Next generation renin inhibitor profiled for difficult-to-treat population- BASEL, Switzerland and BRIDGEWATER, NJ USA, December 10, 2007-Speedel Holding Ltd
3. SPEEDEL ANNOUNCES FINANCIAL RESULTS FOR THIRD QUARTER 2007
Basel/Switzerland and Bridgewater NJ/USA, 14 November 2007 Speedel Holding Ltd (SWX: SPPN) today announced consolidated financial results for the three and nine months ending ...
4. SPEEDEL ANNOUNCES APPOINTMENTS TO BOARD AND MANAGEMENT
April 12, 2007 -- -Annual Report 2006 published and AGM motions notified- Basel/Switzerland and Bridgewater NJ/USA, 12 April 2007 Speedel (SWX: SPPN) announced today changes to ...
5. SPEEDEL REPORTS ON DATA PUBLISHED AT HYPERTENSION 2008 MEDICAL ...
Speedel Holding AG New pre-clinical and clinical data for SPP635 and SPP301
6. Speedel Holding AG: Private Company Information - BusinessWeek
Get Speedel Holding AG company research & investing information. Find executive management and the latest company developments.
7. Speedel Experimenta succeeds with SAS | SAS
Swiss biopharmaceutical company speeds up the drug development process with SAS.
8. Speedel Reports on Data Published at Hypertension 2008 Medical ...
New preclinical and clinical data for SPP635 and SPP301 BASEL Switzerland and BRIDGEWATER N.J. USA, 19 June 2008 Speedel Holding Ltd. (SWX SPPN) today announced
9. Speedel Stops Current SPP301 Phase III Trial in Diabetic Kidney ...
BASEL, Switzerland and BRIDGEWATER, N.J., Dec. 19, 2006 (PRIME NEWSWIRE) -- Speedel (SWX:SPPN) announced today that in the interests of patient safety it has stopped the ...
10. Speedel Focuses Pipeline on Spp301 and Next Generation Renin ...
Speedel Holding Ltd (SWX: SPPN) announced today that it will continue development of SPP301 (avosentan) as a potential breakthrough therapy for diabetic kidney disease, which ...
